P
PPLPHARMA
vs
B
BSE Sensex 30
Over the past 12 months, PPLPHARMA has underperformed BSE Sensex 30, delivering a return of -24% compared to the BSE Sensex 30's +6% growth.
Stocks Performance
PPLPHARMA vs BSE Sensex 30
Performance Gap
PPLPHARMA vs BSE Sensex 30
Performance By Year
PPLPHARMA vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Piramal Pharma Ltd
Glance View
Piramal Pharma Ltd. has embarked on a remarkable journey that reflects the dynamic world of pharmaceuticals and healthcare. Emerging from the rich tapestry of the Piramal Group's diverse business ventures, it has carved out a distinctive place for itself in the global pharmaceutical landscape. The company primarily navigates through three major streams: Contract Development and Manufacturing Organization (CDMO), Critical Care, and Consumer Products. Its CDMO division is the backbone, providing end-to-end solutions spanning the entire drug lifecycle, from development through to commercial manufacturing. By offering tailored solutions to pharmaceutical companies globally, Piramal Pharma not only strengthens its revenue streams but also builds lasting partnerships with some of the world’s leading pharmaceutical innovators. Beyond the realm of CDMO, Piramal Pharma's Critical Care segment specializes in catering to the acute care sector, dealing especially with inhalation anesthesia and pain management solutions. This division operates globally, emphasizing a diligent supply chain that ensures these life-sustaining products reach hospitals and clinics around the world. Meanwhile, its Consumer Products business makes a concerted effort to touch lives in a different manner—through over-the-counter health solutions that meet everyday health concerns of countless individuals. Operating at this unique intersection where science meets humanity, Piramal Pharma not only thrives through product sales but also invests heavily in R&D, seeking out innovative ways to address evolving market needs and inch its way forward in the competitive pharmaceutical arena.
